Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Nehal J. Lakhani, Amita Patnaik, John B. Liao, John William Moroney, David S. Miller, Gini F. Fleming, Matt Axt, Yan V. Wang, Balaji Agoram, Jens-Peter Volkmer, Roy Maute, Andreas Schroeder, Isagani Chico, Mark Chao, Chris H.M. Takimoto, Kathleen N. Moore
Title A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.
Journal
Vol
Issue
Date
URL https://meetinglibrary.asco.org/record/183103/abstract
Abstract Text J Clin Oncol 38, 2020 (suppl 5; abstr 18)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown ovarian cancer not applicable Atezolizumab + Hu5F9-G4 Phase I Actionable In a Phase Ib trial, Tecentriq (atezolizumab) and Magrolimab (Hu5F9-G4) combination therapy demonstrated acceptable safety, and resulted in stable disease as best response in 56% (10/18) of patients with platinum-resistant ovarian cancer (J Clin Oncol 38, 2020 (suppl 5; abstr 18); NCT03558139). detail...
Unknown unknown aggressive digital papillary adenocarcinoma not applicable Atezolizumab + Hu5F9-G4 Case Reports/Case Series Actionable In a Phase Ib trial, Tecentriq (atezolizumab) and Magrolimab (Hu5F9-G4) combination therapy resulted in a partial response lasted 4 months in a patient with papillary adenocarcinoma of the finger (J Clin Oncol 38, 2020 (suppl 5; abstr 18); NCT03558139). detail...
Unknown unknown Advanced Solid Tumor not applicable Atezolizumab + Hu5F9-G4 Phase I Actionable In a Phase Ib trial, Tecentriq (atezolizumab) and Magrolimab (Hu5F9-G4) combination therapy demonstrated acceptable safety, and resulted in a partial response in 7.7% (1/13) of patients with advanced solid tumors (J Clin Oncol 38, 2020 (suppl 5; abstr 18); NCT03558139). detail...